Key Insights

Highlights

Success Rate

50% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

12.5%

2 terminated out of 16 trials

Success Rate

50.0%

-36.5% vs benchmark

Late-Stage Pipeline

13%

2 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed with results

Key Signals

1 with results50% success

Data Visualizations

Phase Distribution

12Total
Not Applicable (4)
P 1 (4)
P 2 (2)
P 3 (2)

Trial Status

Unknown7
Recruiting3
Completed2
Terminated2
Withdrawn1
Not Yet Recruiting1

Trial Success Rate

50.0%

Benchmark: 86.5%

Based on 2 completed trials

Clinical Trials (16)

Showing 16 of 16 trials
NCT07118202Not ApplicableRecruitingPrimary

TheraBionic P1 Device in Subjects With Advanced Hepatocellular Carcinoma

NCT07489768Not Yet Recruiting

GNB4 and Riplet Gene Methylation Combined Detection Kit for Hepatocellular Carcinoma Recurrence Monitoring

NCT06254248Phase 2Recruiting

Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma

NCT05417932Phase 1Recruiting

A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma

NCT05497453Phase 1Terminated

A Phase 1/2 Study to Evaluate OTX-2002 in Patients with Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association with the MYC Oncogene

NCT06233708CompletedPrimary

Association Between Pre-op Non-Selective Beta-Blockers and Hepatocellular Carcinoma Recurrence Post-Liver Transplant

NCT05990959UnknownPrimary

Risk Factors, Prognosis, and Potential Chemoprevention Drugs in Patients With Recurrent Hepatocellular Carcinoma After Curative Surgeries: a Nationwide Retrospective Cohort Study and a Multi-center Prospective Cohort Analysis

NCT05355155Phase 2Unknown

Bevacizumab Biosimilar Plus FOLFOX4 in the Treatment of Recurrent HCC After Liver Transplantation

NCT05277675Not ApplicableUnknownPrimary

Radiofrequency Ablation Plus Systematic Neoadjuvant Therapy for Recurrent Hepatocellular Carcinoma (RANT Study)

NCT02423343Phase 1Completed

A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma

NCT04506398UnknownPrimary

Heterogeneity and Evolution of hepatoceLlular Carcinoma in Post-transplant HCC Recurrence

NCT03563170Phase 1Withdrawn

QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine

NCT04425226Not ApplicableUnknown

Pembrolizumab and LENvatinib in Participants With Hepatocellular Carcinoma (HCC) Before Liver Transplant

NCT04392700Phase 3UnknownPrimary

A RCT of TNF and ENT in the Treatment of Long-term Prognosis With Hepatitis B-related HCC After Curative Resection

NCT03313648Not ApplicableUnknownPrimary

A Study of Laparoscopic Hepatectomy Versus RFA in the Treatment of Recurrent HCC

NCT01009593Phase 3Terminated

Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)

Showing all 16 trials

Research Network

Activity Timeline